## Marianthi Georgitsi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2564115/publications.pdf

Version: 2024-02-01

304368 189595 2,881 50 22 50 citations h-index g-index papers 51 51 51 2888 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Myasthenia gravis genome-wide association study implicates AGRN as a risk locus. Journal of Medical Genetics, 2022, 59, 801-809.	1.5	5
2	Association of rs11780592 Polymorphism in the Human Soluble Epoxide Hydrolase Gene (EPHX2) with Oxidized LDL and Mortality in Patients with Diabetic Chronic Kidney Disease. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-8.	1.9	13
3	Clinical Profiles and Socio-Demographic Characteristics of Adults with Specific Learning Disorder in Northern Greece. Brain Sciences, 2021, 11, 602.	1.1	8
4	The Polygenic Nature and Complex Genetic Architecture of Specific Learning Disorder. Brain Sciences, 2021, 11, 631.	1.1	12
5	Variants in clock genes could be associated with lower risk of type 2 diabetes in an elderly Greek population. Maturitas, 2021, 152, 20-25.	1.0	1
6	Oxidative Stress Genes in Diabetes Mellitus Type 2: Association with Diabetic Kidney Disease. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-10.	1.9	15
7	Association between CUBN gene variants, type 2 diabetes and vitamin D concentrations in an elderly Greek population. Journal of Steroid Biochemistry and Molecular Biology, 2020, 198, 105549.	1.2	7
8	Genetic variation in CARD8, a gene coding for an NLRP3 inflammasome-associated protein, alters the genetic risk for diabetic nephropathy in the context of type 2 diabetes mellitus. Diabetes and Vascular Disease Research, 2020, 17, 147916412097089.	0.9	6
9	Antiâ€dopamine D2 receptor antibodies in chronic tic disorders. Developmental Medicine and Child Neurology, 2020, 62, 1205-1212.	1.1	15
10	European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. European Child and Adolescent Psychiatry, 2019, 28, 91-109.	2.8	36
11	Antibodies to neuronal surface proteins in Tourette Syndrome: Lack of evidence in a European paediatric cohort. Brain, Behavior, and Immunity, 2019, 81, 665-669.	2.0	15
12	Neuropathology-driven Whole-genome Sequencing Study Points to Novel Candidate Genes for Healthy Brain Aging. Alzheimer Disease and Associated Disorders, 2019, 33, 7-14.	0.6	1
13	Assessment of association between lipoxygenase genes variants in elderly Greek population and type 2 diabetes mellitus. Diabetes and Vascular Disease Research, 2018, 15, 340-343.	0.9	7
14	Association of ALOX12 gene polymorphism with all-cause and cardiovascular mortality in diabetic nephropathy. International Urology and Nephrology, 2018, 50, 321-329.	0.6	20
15	Variant Ranker: a web-tool to rank genomic data according to functional significance. BMC Bioinformatics, 2017, 18, 341.	1.2	21
16	Meta-Analysis of Tourette Syndrome and Attention Deficit Hyperactivity Disorder Provides Support for a Shared Genetic Basis. Frontiers in Neuroscience, 2016, 10, 340.	1.4	26
17	The Genetic Etiology of Tourette Syndrome: Large-Scale Collaborative Efforts on the Precipice of Discovery. Frontiers in Neuroscience, 2016, 10, 351.	1.4	45
18	Targeted Re-Sequencing Approach of Candidate Genes Implicates Rare Potentially Functional Variants in Tourette Syndrome Etiology. Frontiers in Neuroscience, 2016, 10, 428.	1.4	29

#	Article	IF	CITATIONS
19	The Genetics of Gilles de la Tourette Syndrome: a Common Aetiological Basis with Comorbid Disorders?. Current Behavioral Neuroscience Reports, 2016, 3, 218-231.	0.6	7
20	Lithium-induced differential expression of SAT1 in suicide completers and controls is not correlated with polymorphisms in the promoter region of the gene. Psychiatry Research, 2014, 220, 1167-1168.	1.7	1
21	Genetic Databases in Pharmacogenomics: The Frequency of Inherited Disorders Database (FINDbase). Methods in Molecular Biology, 2013, 1015, 321-336.	0.4	3
22	Functional analysis of a novel KLF1 gene promoter variation associated with hereditary persistence of fetal hemoglobin. Annals of Hematology, 2013, 92, 53-58.	0.8	22
23	Genomic variation in the <i>MAP3K5</i> gene is associated with $\hat{l}^2$ -thalassemia disease severity and hydroxyurea treatment efficacy. Pharmacogenomics, 2013, 14, 469-483.	0.6	25
24	Genetics of Myasthenia Gravis: A Case-Control Association Study in the Hellenic Population. Clinical and Developmental Immunology, 2012, 2012, 1-7.	3.3	12
25	6-mercaptopurine influences <i>TPMT</i> gene transcription in a <i>TPMT</i> gene promoter variable number of tandem repeats-dependent manner. Pharmacogenomics, 2012, 13, 283-295.	0.6	21
26	$\langle i \rangle$ KLF10 $\langle i \rangle$ gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in $\hat{l}^2$ -hemoglobinopathy patients. Pharmacogenomics, 2012, 13, 1487-1500.	0.6	37
27	Population-ethnic group specific genome variation allele frequency data: A querying and visualization journey. Genomics, 2012, 100, 93-101.	1.3	12
28	A Single Nucleotide Polymorphism in the <i>HBBP1 </i> Gene in the Human $\hat{l}^2$ -Globin Locus is Associated with a Mild $\hat{l}^2$ -Thalassemia Disease Phenotype. Hemoglobin, 2012, 36, 433-445.	0.4	22
29	First Report of Hb A <sub>2</sub> -NYU (HBD:c.39T>A) in the Hellenic Population. Hemoglobin, 2011, 35, 91-95.	0.4	1
30	Evidence for association of an $\langle i \rangle$ ACCN1 $\langle i \rangle$ gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics, 2011, 12, 1559-1569.	0.6	82
31	Population-specific documentation of pharmacogenomic markers and their allelic frequencies in FINDbase. Pharmacogenomics, 2011, 12, 49-58.	0.6	30
32	Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nature Genetics, 2011, 43, 295-301.	9.4	142
33	Transcriptional regulation and pharmacogenomics. Pharmacogenomics, 2011, 12, 655-673.	0.6	16
34	FINDbase: a worldwide database for genetic variation allele frequencies updated. Nucleic Acids Research, 2011, 39, D926-D932.	6.5	22
35	Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nature Genetics, 2010, 42, 801-805.	9.4	323
36	Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line (i>AIP (i) Mutations and Pituitary Adenomas: An International Collaborative Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E373-E383.	1.8	323

3

#	Article	IF	Citations
37	Mice with Inactivation of Aryl Hydrocarbon Receptor-Interacting Protein (Aip) Display Complete Penetrance of Pituitary Adenomas with Aberrant ARNT Expression. American Journal of Pathology, 2010, 177, 1969-1976.	1.9	78
38	MEN-4 and other multiple endocrine neoplasias due to cyclin-dependent kinase inhibitors (p27Kip1 and) Tj ETQq 425-437.	0 0 0 rgB1 2.2	Γ /Overlock 10 52
39	Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene. European Journal of Endocrinology, 2009, 161, 799-804.	1.9	45
40	Impact of ACE and ApoE polymorphisms on myocardial perfusion: correlation with myocardial single photon emission computed tomographic imaging. Journal of Human Genetics, 2009, 54, 595-602.	1.1	10
41	Genetic recombination as a major cause of mutagenesis in the human globin gene clusters. Clinical Biochemistry, 2009, 42, 1839-1850.	0.8	21
42	Aryl hydrocarbon receptor interacting protein mutations seem not to associate with familial non-medullary thyroid cancer. Journal of Endocrinological Investigation, 2009, 32, 426-429.	1.8	12
43	Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition. Journal of Endocrinological Investigation, 2009, 32, 512-518.	1.8	28
44	<i>Aryl hydrocarbon receptor interacting protein</i> ( <i>AIP</i> ) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clinical Endocrinology, 2008, 69, 621-627.	1.2	80
45	Large Genomic Deletions in <i>AIP</i> in Pituitary Adenoma Predisposition. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4146-4151.	1.8	74
46	Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 4101-4105.	3.3	173
47	Germline CDKN1B/p27Kip1 Mutation in Multiple Endocrine Neoplasia. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3321-3325.	1.8	262
48	No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. Endocrine-Related Cancer, 2007, 14, 901-906.	1.6	48
49	Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. British Journal of Cancer, 2007, 96, 352-356.	2.9	56
50	Pituitary Adenoma Predisposition Caused by Germline Mutations in the AIP Gene. Science, 2006, 312, 1228-1230.	6.0	557